Spermosens reported, as planned, no net sales during the first quarter of 2026, in line with the corresponding period last year. Operating loss increased to SEK -2.2 million (-2.1). Earnings per share amounted to SEK -0.001 (-0.002).Total cash flow amounted to SEK -2.4 million (12.6), while cash and cash equivalents at the end of the period amounted to SEK 4.5 million (13.1).The company states that the third generation of the JUNO-Checked diagnostic system was completed during the quarter. In April, a clinical validation study was also initiated at the Reproductive Medicine Centre in Malmö. The study is expected to be completed before the end of 2026.During the quarter, Spermosens signed memorandums of understanding with Sapyen and RSI Reproductive Solutions to promote diagnostics in male fertility, among other markets in the United States. The company states that discussions are ongoing with potential partners in the United States, Europe and Asia with the aim of turning the dialogues into formal agreements during 2026.Spermosens further states that the capital raised at the beginning of 2025, together with a reduced burn rate, provides funding until mid-2026. The company is also working on a financing solution to bridge the period until potential licensing agreements and warrant exercise in November 2026.Key figures, SEK millionQ1 2026Q1 2025ChangeRevenue00Operating profit/loss-2.2-2.15%Cash flow-2.412.6Cash and cash equivalents4.513.1-66%Earnings per share, SEK-0.001-0.002